The FDA Wants Huntington's Patients to Wait 5 Years for a Placebo Brain Surgery
The FDA granted AMT-130 Breakthrough Therapy and RMAT designations in June 2025, endorsing an external control pathway. By November, the agency reversed itself and demanded sham brain surgery. The patients stuck in that gap are losing irreplaceable years.
By Crash Davis · 3 min read